Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of UC at least three months prior to screening, and with a minimum disease extent of 15 cm from the anal verge~* Active mild-to-moderate UC~* Inadequate response to, loss of response to, or intolerance of, at least one of the following conventional therapies: 5-ASA compounds, corticosteroids, 6-mercaptopurine (6-MP) or azathioprine (AZA), anti-TNFα, anti-integrin or tofacitinib~Exclusion Criteria:~* Known history of Crohn's disease~* No previous history of treatment for UC (treatment-naïve)~* Subjects on steroid medication who are unable to have steroids tapered and be completely off steroids at least two weeks prior to screening~* Unable to stop steroid enemas or suppositories, or 5-ASA enemas or suppositories, at least two weeks prior to screening~* Subjects who have received any investigational or approved biologic therapy within eight weeks or five half-lives prior to screening (whichever is longer)~* Subjects who have received any investigational or approved non-biologic therapy, except for those specifically listed in the Permitted Concomitant Medications, for the treatment of underlying disease, within 30 days or five half-lives prior to screening (whichever is longer)~* Major gastrointestinal surgery (not including appendectomy or cholecystectomy) within two months before screening, or any history of total colectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (after placebo pre-treatment) (Type: PLACEBO_COMPARATOR): Once-daily dosing of Placebo (after placebo pre-treatment)
- SER-287 Induction Dosing (after vancomycin pre-treatment) (Type: EXPERIMENTAL): Once-daily dosing of SER-287 (Induction Dose, after vancomycin pre-treatment)
- SER-287 Step-Down Induction Dosing (after vancomycin pre-treatment) (Type: EXPERIMENTAL): Once-daily dosing of SER-287 (Step-Down Induction Dose, after vancomycin pre-treatment)

Based on this trial design, predict the completion outcome and termination type (if applicable).